08.07.2015 • NewsDede Willamscapacity expansionEvonik

Evonik Expands C4 Output at Antwerp and Marl

German chemical producer Evonik has increased production capacity for C4 products at its sites in Antwerp, Belgium, and Marl, Germany.

The investment, said to be in the triple-digit million euro range, includes additional capability to produce butadiene, the plasticizer isononanol and the antiknock agent MTBE.

In announcing the plans two years ago, Evonik said the expansion would be a step toward lifting its butadiene output in Antwerp by 100,000 t/y, and its output of MTBE at Marl and Antwerp together would rise by 150,000 t/y up to 2015.

Citing market analyses that global demand is increasing by 2-5% annually, the Essen-based company said it is “sustainably strengthening” its market positions and supporting its customers growth plans.

Evonik said it has secured raw materials supply to the new production facilities with long-term contracts. Additionally, for the first time it has made FCC-C4 material flows from refineries usable.

Along with being “a globally leading provider” of the products being expanded as well as other C-4 products, including isobutene, 1-butene, 2-PH (2-propylheptanol) and the plasticizer DINP (diisononylphthalate), the German chemical producer also operates integrated large-scale plants for processing C4 starting materials.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.